17. July 2025

ARQIS has provided comprehensive legal advice to biotechnology start-up EvlaBio GmbH, developer of innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, on its seed financing round. EvlaBio raised a total of EUR 21 million in seed capital to advance the completion of preclinical development and the transition into IND-enabling studies. The financing round was led by the French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.Bank) and High-Tech Gründerfonds as co-investors. It is one of the largest financing rounds of its kind in the DACH region in recent years.

The start-up's treatment approach originally comes from Lead Discovery Center GmbH (LDC), a company founded in 2008 by the technology transfer organization Max Planck Innovation, and was developed in collaboration with KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I).

EvlaBio, with offices in Düsseldorf and Zurich, is a life science start-up specializing in the development of a first-in-class therapeutic for the treatment of left ventricular hypertrophy for patients with chronic kidney disease.

An ARQIS team headed by partner Dr. Mauritz von Einem, who regularly advises start-ups, provided EvlaBio AG with comprehensive legal advice in connection with this financing round. The mandate arose from a personal contact to the founder of EvlaBio. Advestra provided advice on Swiss law through a team led by Dr. Alexander von Jeinsen.

Advisor to EvlaBio GmbH
ARQIS (Munich): Partner: Dr. Mauritz von Einem (Partner, Transactions, Venture Capital, Lead), Johannes Landry (Transactions, Düsseldorf), Lisa-Marie Niklas (HR.Law, Düsseldorf), Marcus Nothhelfer (IP), of Counsel: Prof. Dr. Christoph von Einem (Transactions, Venture Capital), Counsel: Jens Knipping (Düsseldorf), Dennis Reisich (both Tax), Dr. Roua Schmitz (HR.Law), Nora Stratmann (Commercial), Managing Associates: Dr. Hanna Caesar (HR.Law, Düsseldorf), Anselm Graf (Transactions, Venture Capital), Rolf Tichy (IP), Associate: Giulia Kögel (Transactions, Venture Capital)